[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
January 1997

Presence and Treatment of Vascular Risk Factors in Patients With Vascular Cognitive Impairment

Author Affiliations

From the Division of Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia (Dr Rockwood); the Division of Geriatric Medicine, University of Calgary, Alberta (Drs Ebly and Hogan); and the Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario (Dr Hachinski).

Arch Neurol. 1997;54(1):33-39. doi:10.1001/archneur.1997.00550130019010
Abstract

Objective:  To document the presence and treatment of selected vascular risk factors in patients with vascular cognitive impairment and elements affecting undertreatment of vascular risk factors.

Design:  Secondary analysis of the Canadian Study of Health and Aging database, which is a national, representative, cross-sectional study of the epidemiologic distribution of dementia in elderly people in Canada.

Setting:  Survey.

Patients:  Institutionalized and community-dwelling elderly people.

Main Outcome Measures:  Vascular risk factors, dementia diagnosed by standard methods, and medication use.

Results:  Treatable vascular risk factors occurred significantly more often in patients with vascular cognitive impairment (with and without dementia) than in patients with probable Alzheimer disease or normal cognitive function. For example, 76% of patients with vascular dementia and 57% of those with vascular cognitive impairment without dementia had a history of stroke, compared with only 5% of those with probable Alzheimer disease and 7% of those with no cognitive loss. (For hypertension, the comparable figures are 55%, 48%, 24%, and 38%, respectively.) Potential undertreatment of vascular risk factors had little effect on mean control of vascular risk factors. For example, the mean (±SD) systolic blood pressure in those being treated was 144±26 mm Hg, compared with 142±25 mm Hg in those not receiving pharmacological treatment. In each group (treated vs untreated), the proportion of patients with a systolic blood pressure higher than 160 mm Hg was 20% and 16%, respectively. Potential undertreatment occurred most often in those with severe dementia and those living in nursing homes.

Conclusions:  Vascular risk factors occurred more commonly in patients with vascular cognitive impairment compared with other patients, including those with other forms of dementia. When present, such risk factors were often treated pharmacologically, except in patients with severe dementia and those in long-term care institutions. Undertreatment does not, in general, result in worsened risk factor control.

References
1.
Hachinski V.  Preventable senility: a call for action against the vascular dementias . Lancet . 1992;340:645-648.Article
2.
Erkinjuntti T, Hachinski V.  Rethinking vascular dementia . Cerebrovasc Dis . 1993; 3:3-23.Article
3.
Hachinski V.  Vascular dementia: a radical redefinition . Dementia . 1994;5:130-132.
4.
Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R.  Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers . Neurology . 1992; 42:473-480.Article
5.
Roman GC, Tatemichi TK, Erkinjuntti T, et al.  Vascular dementia—diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop . Neurology . 1993;43:250-260.Article
6.
Erkinjuntti T, Haltia M, Palo J, Sulkava R, Paetau A.  Accuracy of the clinical diagnosis of vascular dementia: a prospective clinical and postmortem neuropathological study . J Neurol Neurosurg Psychiatry . 1988;51:1037-1044.Article
7.
World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) . Geneva, Switzerland: World Health Organization; 1992:25-31.
8.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition. Washington, DC: American Psychiatric Association; 1994:143-146.
9.
Roth M, Huppert FA, Tym E, Mountjoy CQ, eds. CAMDEX: The Cambridge Examination for Mental Disorders of the Elderly . Cambridge, Mass: Cambridge University Press; 1988.
10.
Rockwood K, Parhad I, Hachinski V, et al.  Diagnosis of vascular dementia: Consortium of Canadian Centres for Clinical Cognitive Research concensus statement . Can J Neurol Sci . 1994;21:358-364.
11.
Starr JM, Whalley LJ.  Senile hypertension and cognitive impairment: an overview . J Hypertens . 1992;10( (suppl) ):31-42.
12.
Meyer JS, Judd BW, Tawaklna T, et al.  Improved cognition after control of risk factors for multi-infarct dementia . JAMA . 1986;256:2203-2209.Article
13.
Meyer JS, Rogers RL, McClintic K, et al.  Randomized clinical trial of daily aspirin therapy in multi-infarct dementia . J Am Geriatr Soc . 1989;37:549-555.
14.
Cebul RD.  Aspirin and MID . J Am Geriatr Soc . 1989;37:573-575.
15.
Meyer JS, Muramatsu K, Mortel KF, et al.  Prospective CT confirms differences between vascular and Alzheimer's dementia . Stroke . 1995;26:735-742.Article
16.
Hogan DB, Ebly EM, Fung TS.  Regional variations in the use of potentially inappropriate medications by Canadian seniors participating in the Canadian Study of Health and Aging . Can J Clin Pharmacol . 1995;2:167-174.
17.
Krumholz HM, Radford MJ, Ellerbeck EF, et al.  Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes . Ann Intern Med . 1996;124:292-298.Article
18.
Canadian Study of Health and Aging Working Group.  Canadian Study of Health and Aging: study methods and prevalence of dementia . Can Med Assoc J . 1994; 150:899-913.
19.
Graham JE, Rockwood K, Beattie BL, et al.  Standardization of the diagnosis of dementia in the Canadian Study of Health and Aging . Neuroepidemiology . 1996; 15:246-256.Article
20.
Ebly E, Hogan D, Parhad I.  Cognitive impairment in the nondemented elderly . Arch Neurol . 1995;52:612-619.Article
21.
Canadian Study of Health and Aging.  The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada . Neurology . 1994;44:2073-2080.Article
22.
Teng EL, Chui HC.  The modified Mini-Mental State (3MS) examination . J Clin Psychiatry . 1987;48:314-318.
23.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders , Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987:133-136.
24.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease . Neurology . 1984;34:939-944.Article
25.
Tuokko H, Kristjansson E, Miller J.  The neuropsychological detection of dementia: an overview of the neuropsychological tests fielded in the Canadian Study of Health and Aging . J Clin Exp Neuropsychol . 1995;17:352-373.Article
26.
Hachinski VC, Iloff L, Zilkha K, et al.  Multi-infarct dementia . Arch Neurol . 1975; 32:632-637.Article
27.
Scheinberg P.  Dementia due to vascular disease: a multifactorial disorder . Stroke . 1988;19:1291-1299.Article
28.
Applegate WB.  High blood pressure treatment in the elderly . Clin Geriatr Med . 1992;8:103-118.
29.
LaCroix AZ, Omenn GS.  Older adults and smoking . Clin Geriatr Med . 1992;8:69-88.
30.
Dalen JE, Goldberg RJ.  Prophylactic aspirin and the elderly population . Clin Geriatr Med . 1992;8:119-126.
31.
Roos NP, Shapiro E.  The Manitoba longitudinal study on aging: preliminary findings on health care utilization by the elderly . Med Care . 1981;19:644-657.Article
32.
Marshall VW.  Factors affecting response and completion rates in some Canadian studies . Can J Aging . 1987;6:217-227.Article
33.
Rockwood K, Stolee P, Robertson D, Shillington ER.  Response bias in a health status survey of elderly people . Age Ageing . 1989;18:177-182.Article
34.
Skoog I, Nilsson L, Palmertz B, Andreasson L, Svanborg A.  A population-based study of dementia in 85-year-olds . N Engl J Med . 1993;328:153-158.Article
35.
Hébert R, Bravo G, Korner-Bitensky N, Vogen L.  Refusal and information bias associated with postal questionnaires in very elderly subjects . J Clin Epidemiol . 1996;49:373-381.Article
36.
Rockwood K, Tripp DA, Stadnyk K, Fisk J.  Screening for cognitive impairment in the elderly: impact of physical function measures added to cognitive screening instruments . Aging Cognition . 1994;1:261-270.Article
37.
Grace J, Nadler JD, White DA, et al.  Folstein vs modified Mini-Mental State Examination in geriatric stroke: stability, validity, and screening utility . Arch Neurol . 1995;52:477-484.Article
38.
Launer LJ, Masaki K, Petrovitch H, et al.  The association between midlife blood pressure levels and late-life cognitive function . JAMA . 1995;274:1846-1851.Article
39.
Ferruci L, Guralnick JM, Salive ME, et al.  Cognitive impairment and the risk of stroke in the older population . J Am Geriatr Soc . 1996;44:237-241.
40.
White L.  Is silent cerebrovascular disease an important cause of late-life cognitive decline? J Am Geriatr Soc . 1996;44:328-329.
41.
Skoog I, Lernfelt B, Landahl S, et al.  15-Year longitudinal study of blood pressure and dementia . Lancet . 1996;347:1141-1145.Article
42.
Martyn C.  Blood pressure and dementia . Lancet . 1996;347:1130-1131.Article
43.
Gale CR, Martyn CN, Cooper G.  Cognitive impairment and mortality in a cohort of elderly people . BMJ . 1996;312:608-611.Article
44.
Persson G, Skoog I.  Subclinical dementia: relevance of cognitive symptoms and signs . J Geriatr Psychiatry Neurol . 1992;5:172-178.Article
45.
Black RS, Bardy LL, Nolan KA, et al.  Pentoxifylline in cerebrovascular dementia . J Am Geriatr Soc . 1992;40:237-244.
46.
Villardita C, Grioli S, Lomeo C, et al.  Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia . Neuropsychobiology . 1992;25:24-28.Article
47.
Cucinotta D, Aveni-Casucci MA, Pedrazzi F, et al.  Multicentre clinical placebo-controlled study with buflomedil in the treatment of mild dementia of vascular origin . J Int Med Res . 1992;20:136-149.
48.
Parnetti L, Senin U, Carosi M, Baasch H.  Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine . Clin Ther . 1993;15:394-406.
49.
Saletu B, Paulus E, Linzmayer L, et al.  Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study . Psychopharmacology (Berl) . 1995;117:385-395.Article
×